# Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

> **NCT07211958** · PHASE3 · RECRUITING · sponsor: **Syndax Pharmaceuticals** · enrollment: 468 (estimated)

## Conditions studied

- Acute Myeloid Leukemias

## Interventions

- **DRUG:** Revumenib
- **DRUG:** Placebo
- **DRUG:** Intensive Chemotherapy Regimen

## Key facts

- **NCT ID:** NCT07211958
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-25
- **Primary completion:** 2029-06
- **Final completion:** 2031-01
- **Target enrollment:** 468 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07211958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07211958, "Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07211958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*